Company: REVB
Filing Date: 2025-04-04
Form Type: DRS
Source: 0001213900-25-029022
Chunk: 9

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-04-04
Form: DRS
Chunk 9
---
 clinical study was announced in June of 2024, showing a significant increase in anti -inflammatorycytokines including IL -1RAand IL -10. In January of 2025 we announced the start of our Phase 1b clinical study in CKD patients. The Phase 1b clinical study will support further development of Gemini -AKI. We expect data from our Phase 1b clinic study in the first half of this year. Gemini-CKD The Gemini -CKDprogram is being developed as a potential therapy for preventing the progression of CKD. We believe Gemini may modulate the immune response from a pro -inflammatorystate to an anti -inflammatory(protective) state to rebalance the innate immune response and slow down or halt the progressive destruction and scarring of organ tissue, allowing the healing process to take place. Preclinical studies have demonstrated that Gemini significantly reduces the degree of scar tissue formation in a hyperinflammatory kidney injury model. In January of 2025 we announced the start of our Phase 1b clinical study in CKD patients. The Phase 1b clinical study will support further development of Gemini -CKD. We expect data from our Phase 1b clinic study in the first half of this year. Gemini-PSI The Gemini -PSIprogram is being developed, through a license agreement with Vanderbilt University, as a potential therapy for the prevention or treatment of surgical site infection. We believe immunologic preconditioning with Gemini prepares the body to resist infection by priming the body’s immune system to better and more rapidly respond to pathogen exposure. Multiple preclinical studies have shown that systemic pretreatment with PHAD results in a significantly augmented immune response leading to significantly reduced duration and severity of infection following bacterial challenge with either gram -positiveor gram -negativebacteria. Gemini-PBI The Gemini -PBIprogram is being developed, through a license agreement with Vanderbilt University, as a potential therapy for the prevention of infection in severe burn patients requiring hospitalization. We believe Gemini administration to severe burn patients will augment the patients immune response to resist infection by activating the body’s immune system to better and more rapidly respond to pathogen exposure. Preclinical studies in a burn model have shown that systemic administration of MPLA (a bacterially derived mixture of PHAD -likemolecules) post -burnresults in a significantly augmented immune response leading to significantly reduced duration and severity of infection following pseudomonas challenge. Our Corporate History and Team The Company was incorporated in the state of Delaware